Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
- Sponsor
- Rep. Brown, Shontel M. [D-OH-11]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 15, 2025
Bottom line
The bill establishes federal programs for research, grants, and public awareness to improve early detection and intervention for uterine fibroids and related gynecological health issues, particularly focusing on underserved communities.
What it actually does
This bill authorizes the Secretary of Health and Human Services (HHS) to conduct and support research aimed at increasing the early detection and intervention for uterine fibroids. It also authorizes HHS to award grants to states for programs that enhance early detection, intervention, and public awareness campaigns for uterine fibroids, with a priority for socially vulnerable populations. Additionally, the bill authorizes grants for research, including clinical trials, on disparities in pain management for uterine fibroid surgical treatment and other intrauterine conditions.
Proponents argue
Supporters argue that this bill addresses a significant public health issue affecting millions of women, particularly women of color, by promoting early detection and intervention which can lead to better health outcomes and potentially less invasive treatments. They contend that focusing on socially vulnerable populations is crucial for reducing health disparities and ensuring equitable access to care and information.
Opponents contend
Critics might argue that while the intent is laudable, the bill authorizes new spending without specifying a funding mechanism, potentially contributing to the national deficit if not offset. Some may also contend that the scope of research and grant activities, while important, could be more effectively integrated into existing federal health programs rather than creating new ones.
The bill is short and clearly written, making it highly accessible for a reader to understand its provisions and implications within a short timeframe.
Section 2
Research on Uterine Fibroid Early Detection and Intervention
This section directs the Secretary of Health and Human Services to either conduct or support research focused on improving the early detection and intervention methods for uterine fibroids. Based on this research, the Secretary is required to develop evidence-based or evidence-informed strategies to enhance early detection in healthcare settings. These strategies are to be finalized quickly to be used by states receiving grants under the bill.
Supporters argue
Proponents argue that robust federal research is essential to advance medical understanding and develop effective, standardized approaches for early detection, which is critical for managing uterine fibroids and improving patient outcomes.
Critics contend
No specific opposition is typically raised against federal funding for medical research, though some may argue for greater prioritization of specific research areas or more efficient allocation of existing research funds.
Tradeoffs
The primary tension involves balancing the urgency of developing strategies with the thoroughness required for evidence-based research, ensuring that strategies are both timely and scientifically sound.
Section 3
Grants for Uterine Fibroid Early Detection and Intervention Programs
This section authorizes the Secretary of HHS to award grants to states. These grants are intended to fund programs that increase early detection and intervention for uterine fibroids, and to create public awareness and education campaigns. States can use these funds for activities such as advanced gynecological imaging (including payment for these services), patient navigation, implementing evidence-based strategies, and improving access to healthcare settings. Priority for these grants is given to states serving socially vulnerable populations at higher risk of uterine fibroid development.
Section 4
Grants for Specific Uterine Fibroid Related Research
This section authorizes the Secretary of HHS to award grants specifically for research, which can include clinical trials, on two key areas. First, it targets disparities in pain control and management during uterine fibroid surgical treatment. Second, it focuses on Asherman's Syndrome, intrauterine adhesions, and other related intrauterine conditions as deemed appropriate by the Secretary. This expands the research scope beyond just detection and intervention for fibroids themselves.